

Edmund K Waller

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7571931/edmund-k-waller-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

230
papers

8,102
citations

42
h-index

85
g-index

242
ext. papers

10,298
ext. citations

5.2
avg, IF

5.79
L-index

#	Paper	IF	Citations
230	Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2019 , 380, 45-56	59.2	1385
229	Peripheral-blood stem cells versus bone marrow from unrelated donors. <i>New England Journal of Medicine</i> , 2012 , 367, 1487-96	59.2	620
228	Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4199-206	2.2	384
227	The role of sargramostim (rhGM-CSF) as immunotherapy. <i>Oncologist</i> , 2007 , 12 Suppl 2, 22-6	5.7	311
226	Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Blood</i> , 2011 , 117, 6963-70	2.2	283
225	Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. <i>Journal of Immunology</i> , 2012 , 189, 5082-8	5.3	253
224	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017 , 130, 2243-2250	2.2	220
223	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3141-9	2.2	170
222	Lymphoid Reconstitution After Autologous PBSC Transplantation With FACS-Sorted CD34+ Hematopoietic Progenitors. <i>Blood</i> , 1998 , 91, 2588-2600	2.2	154
221	Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. <i>Blood</i> , 2001 , 97, 2948-56	2.2	119
220	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013 , 121, 197-206	2.2	106
219	Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 460-71	4.7	104
218	CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR repertoire. <i>Blood</i> , 2015 , 125, 3835-50	2.2	102
217	Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 89-97	4.7	99
216	Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFN- γ Licensing. <i>Stem Cells</i> , 2016 , 34, 2429-42	5.8	94
215	In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1638-49	4.7	84
214	Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. <i>Transfusion</i> , 2011 , 51, 2175-82	2.9	84

213	Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease. <i>Circulation Research</i> , 2015 , 116, 289-297	15.7	79
212	Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 116-23	4.7	79
211	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1583-1589	13.4	78
210	Vaccinia Virus Tropism for Primary Hematolymphoid Cells Is Determined by Restricted Expression of a Unique Virus Receptor. <i>Journal of Virology</i> , 2006 , 80, 3126-3126	6.6	78
209	Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. <i>Blood</i> , 2018 , 132, 2506-2519	2.2	78
208	Metabolomics of ADSOL (AS-1) red blood cell storage. <i>Transfusion Medicine Reviews</i> , 2014 , 28, 41-55	7.4	68
207	IFN- λ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. <i>Blood</i> , 2012 , 119, 1075-85	2.2	67
206	Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. <i>Blood</i> , 2002 , 99, 1085-8	2.2	67
205	Autoimmune neutropenia in adults. <i>Autoimmunity Reviews</i> , 2009 , 9, 62-6	13.6	64
204	The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018 , 9, 2166	8.4	63
203	Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2365-72	2.2	62
202	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1636-1645	4.7	56
201	Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1347-53	4.7	53
200	Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. <i>Nature Communications</i> , 2018 , 9, 3698	17.4	53
199	Irradiated Donor Leukocytes Promote Engraftment of Allogeneic Bone Marrow in Major Histocompatibility Complex Mismatched Recipients Without Causing Graft-Versus-Host Disease. <i>Blood</i> , 1999 , 94, 3222-3233	2.2	51
198	Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <i>Immunotherapy</i> , 2009 , 1, 599-621	3.8	51
197	Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
196	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50

195	Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K inhibitors and VIP antagonists. <i>Blood Advances</i> , 2018 , 2, 210-223	7.8	50
194	Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity. <i>PLoS Pathogens</i> , 2015 , 11, e1004770	7.6	49
193	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. <i>Blood Advances</i> , 2018 , 2, 299-307	7.8	47
192	Telomere Shortening, Regenerative Capacity, and Cardiovascular Outcomes. <i>Circulation Research</i> , 2017 , 120, 1130-1138	15.7	46
191	Building blocks for institutional preparation of CTL019 delivery. <i>Cytotherapy</i> , 2017 , 19, 1015-1024	4.8	46
190	Microfluidic Sorting of Cells by Viability Based on Differences in Cell Stiffness. <i>Scientific Reports</i> , 2017 , 7, 1997	4.9	43
189	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016 , 173, 96-104	4.5	43
188	CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2001 , 49, 629-40	7.4	42
187	Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. <i>Science Translational Medicine</i> , 2015 , 7, 315ra191	17.5	41
186	Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. <i>Cancer Medicine</i> , 2014 , 3, 215-24	4.8	40
185	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. <i>Blood Advances</i> , 2020 , 4, 560-572	7.8	40
184	Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity. <i>Journal of Immunology</i> , 2011 , 187, 5130-40	5.3	39
183	A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 848-57	4.7	38
182	Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination. <i>Science</i> , 2020 , 370, 237-241	33.3	36
181	Allotransplantation for patients age ≥0 years with non-Hodgkin lymphoma: encouraging progression-free survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 960-8	4.7	34
180	Microfluidic cell sorting by stiffness to examine heterogenic responses of cancer cells to chemotherapy. <i>Cell Death and Disease</i> , 2018 , 9, 239	9.8	33
179	High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 979-85	4.7	33
178	The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. <i>Oncotarget</i> , 2016 , 7, 2936-50	3.3	33

177	Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 21-30	4.4	32
176	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2002-2007	4.7	32
175	Circadian variation in vascular function and regenerative capacity in healthy humans. <i>Journal of the American Heart Association</i> , 2014 , 3, e000845	6	32
174	Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells. <i>Blood</i> , 2016 , 128, 2568-2579	2.2	32
173	Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. <i>Blood Advances</i> , 2019 , 3, 2230-2236	7.8	32
172	Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 1403-1415	21.7	32
171	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	30
170	Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1287-94	4.7	29
169	Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 540-51	4.7	29
168	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 466-471.e1	2	29
167	Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 629-637	7.8	28
166	New cancers after autotransplantations for multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 738-45	4.7	28
165	Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 616-32	4.7	28
164	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , 2019 , 94, 446-454	7.1	28
163	Microfluidic generation of transient cell volume exchange for convectively driven intracellular delivery of large macromolecules. <i>Materials Today</i> , 2018 , 21, 703-712	21.8	27
162	Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 202-8	4.7	27
161	Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. <i>Transfusion</i> , 2015 , 55, 259-64	2.9	27
160	Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFN γ priming. <i>Blood Advances</i> , 2017 , 1, 628-643	7.8	26

159	Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 852-857	4.7	25
158	Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 934-40	4.7	25
157	Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. <i>Journal of Immunology</i> , 2011 , 187, 1057-65	5.3	25
156	Chronic GvHD decreases antiviral immune responses in allogeneic BMT. <i>Blood</i> , 2007 , 109, 4548-56	2.2	25
155	Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. <i>Blood Cells, Molecules, and Diseases</i> , 2004 , 33, 233-7	2.1	25
154	Circulating Progenitor Cells Identify Peripheral Arterial Disease in Patients With Coronary Artery Disease. <i>Circulation Research</i> , 2016 , 119, 564-71	15.7	24
153	Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 2631-9	27.4	24
152	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. <i>Blood Advances</i> , 2019 , 3, 2836-2844	7.8	24
151	Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. <i>Journal of Immunology</i> , 2003 , 171, 6023-31	5.3	23
150	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 464-476	8.9	23
149	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018 , 2, 933-940	7.8	23
148	Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes. <i>Circulation Research</i> , 2018 , 122, 1565-1575	15.7	22
147	Sex Differences in Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	21
146	A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018 , 103, 1915-1924	6.6	21
145	KIR Donor Selection: Feasibility in Identifying better Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e28-e32	4.7	21
144	Activation, immune polarization, and graft-versus-leukemia activity of donor T cells are regulated by specific subsets of donor bone marrow antigen-presenting cells in allogeneic hemopoietic stem cell transplantation. <i>Journal of Immunology</i> , 2009 , 183, 7799-809	5.3	21
143	Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. <i>PLoS ONE</i> , 2014 , 9, e96165	3.7	21
142	A Prospective Trial of Extracorporeal Photopheresis for Chronic Graft-versus-Host Disease Reveals Significant Disease Response and No Association with Frequency of Regulatory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2373-2380	4.7	20

141	Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. <i>Molecular Cancer Research</i> , 2019 , 17, 2395-2409	6.6	19
140	Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. <i>Transfusion</i> , 2010 , 50, 2424-31	2.9	19
139	Reconstructing immunity after allogeneic transplantation. <i>Immunologic Research</i> , 2004 , 29, 269-82	4.3	19
138	Modulation of antitumor immune responses by hematopoietic cytokines. <i>Cancer</i> , 2003 , 97, 1797-809	6.4	19
137	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. <i>Blood Advances</i> , 2020 , 4, 740-754	7.8	19
136	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 521-528	4.7	19
135	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1865-1877	2.2	18
134	Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2250-2263	7.8	18
133	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. <i>Transfusion</i> , 2007 , 47, 629-35	2.9	16
132	HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. <i>Blood</i> , 2021 , 138, 273-282	2.2	15
131	Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 206-13		14
130	Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1393-5	4.7	14
129	Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 895-904	4.7	14
128	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 270-278	4.7	14
127	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study 2020 , 8,		13
126	Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. <i>Blood Advances</i> , 2019 , 3, 875-883	7.8	13
125	Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 973-982	4.7	12
124	Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1197-1205	4.7	12

123	Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. <i>Journal of Immunology</i> , 2008 , 180, 6892-902	5.3	11
122	Cellular immunotherapy and cancer. <i>Seminars in Oncology</i> , 2004 , 31, 87-90	5.5	11
121	Circulating Progenitor Cells and Racial Differences. <i>Circulation Research</i> , 2018 , 123, 467-476	15.7	11
120	Impact of the posttransplant lymphoproliferative disorder subtype on survival. <i>Cancer</i> , 2018 , 124, 2327-2336	23.6	10
119	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women@ Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD). <i>Atherosclerosis</i> , 2016 , 253, 111-117	3.1	10
118	Flow cytometric data analysis of circulating progenitor cell stability. <i>Data in Brief</i> , 2017 , 10, 346-348	1.2	9
117	Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination. <i>Journal of Virology</i> , 2020 , 94,	6.6	9
116	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020 , 105, 1329-1338	6.6	9
115	Cardiovascular Risk and Resilience Among Black Adults: Rationale and Design of the MECA Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e015247	6	9
114	Evaluation of the spectra Optia [®] mononuclear cell collection procedure in multiple myeloma patients. <i>Journal of Clinical Apheresis</i> , 2015 , 30, 1-7	3.2	9
113	Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 552-8	4.7	9
112	PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients. <i>PLoS ONE</i> , 2017 , 12, e0184254	3.7	9
111	Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1331-9	4.7	8
110	VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. <i>PLoS ONE</i> , 2013 , 8, e63381	3.7	8
109	Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 746-7	4.7	8
108	Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 169-80	4.7	8
107	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). <i>Blood</i> , 2015 , 126, 543-543	2.2	8
106	Flt3L Treatment of Bone Marrow Donors Increases Graft Plasmacytoid Dendritic Cell Content and Improves Allogeneic Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1075-1084	4.7	8

105	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1875-1883	4.7	7
104	Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 383-9	1.9	7
103	Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling. <i>Cancer Research</i> , 2016 , 76, 6802-6815	10.1	7
102	Circulating Progenitor Cells is Linked to Cognitive Decline in Healthy Adults. <i>American Journal of the Medical Sciences</i> , 2016 , 351, 147-52	2.2	7
101	From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. <i>BioMed Research International</i> , 2013 , 2013, 929842	3	7
100	Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients. <i>Blood</i> , 2013 , 121, 2347-51	2.2	7
99	Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice. <i>PLoS ONE</i> , 2013 , 8, e64837	3.7	7
98	Myeloablative busulfan/cytosan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 837-843	1.9	7
97	Myocardial Ischemia and Mobilization of Circulating Progenitor Cells. <i>Journal of the American Heart Association</i> , 2018 , 7, e007504	6	6
96	Similar survival for patients undergoing reduced-intensity total body irradiation (TBI) versus myeloablative TBI as conditioning for allogeneic transplant in acute leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 360-9	4	6
95	Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 16	22.4	6
94	Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT. <i>Experimental Hematology</i> , 2006 , 34, 895-904	3.1	6
93	Irradiated Donor Leukocytes Promote Engraftment of Allogeneic Bone Marrow in Major Histocompatibility Complex Mismatched Recipients Without Causing Graft-Versus-Host Disease. <i>Blood</i> , 1999 , 94, 3222-3233	2.2	6
92	Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary Artery Disease. <i>JAMA Cardiology</i> , 2020 , 5, 147-155	16.2	6
91	Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	6
90	The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples. <i>Blood Advances</i> , 2019 , 3, 2465-2469	7.8	6
89	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1325-1330	4.7	5
88	Chemokine and lymph node homing receptor expression on pDC vary by graft source. <i>Oncolmmunology</i> , 2014 , 3, e958957	7.2	5

87	Natural suppressor cells; past, present and future. <i>Frontiers in Bioscience - Elite</i> , 2012 , 4, 1237-45	1.6	5
86	Changes in the pattern of TCR V beta repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans. <i>British Journal of Haematology</i> , 2001 , 113, 224-30	4.5	5
85	PI3K γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> , 2022 , 139, 523-537	2.2	5
84	Natural suppressor cells past present and future. <i>Frontiers in Bioscience - Elite</i> , 2012 , E4, 1237-1245	1.6	5
83	Indole derivatives, microbiome and graft versus host disease. <i>Current Opinion in Immunology</i> , 2021 , 70, 40-47	7.8	5
82	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 699-711	4.7	5
81	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1744-1755	4.7	4
80	Evaluation of peripheral blood stem cell quality in products transported by traditional courier or commercial overnight shipping services. <i>Transfusion</i> , 2014 , 54, 1501-7	2.9	4
79	Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity. <i>Oncotarget</i> , 2017 , 8, 81873-81879	3.3	4
78	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
77	Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. <i>Haematologica</i> , 2019 , 104, 844-854	6.6	4
76	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	4
75	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 514-8	2	3
74	Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples. <i>British Journal of Haematology</i> , 2018 , 182, 887-894	4.5	3
73	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. <i>Transfusion</i> , 2013 , 53, 76-84	2.9	3
72	Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. <i>Transfusion</i> , 2015 , 55, 2351-7	2.9	3
71	Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2011 , 5, 372	1.2	3
70	Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients. <i>Blood</i> , 2018 , 132, 899-899	2.2	3

69	Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3044-3044	2.2	3
68	Stiffness based enrichment of leukemia cells using microfluidics. <i>APL Bioengineering</i> , 2020 , 4, 036101	6.6	3
67	Vascular Regenerative Capacity and the Obesity Paradox in Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 2097-2108	9.4	3
66	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019 , 125, 185-193	6.4	3
65	Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?. <i>Cancer</i> , 2019 , 125, 838-842	6.4	3
64	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- β and γ . <i>Frontiers in Immunology</i> , 2021 , 12, 718621	8.4	3
63	Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 ,	7.8	3
62	GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration. <i>Molecular Therapy</i> , 2017 , 25, 416-426	11.7	2
61	Mobilizing plasmacytoid dendritic cells. <i>Blood</i> , 2017 , 129, 2600-2602	2.2	2
60	Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia. <i>Oncotarget</i> , 2017 , 6, e1304336	7.2	2
59	Circulating Progenitor Cells and Cognitive Impairment in Men and Women with Coronary Artery Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 659-668	4.3	2
58	New molecule for mobilizing marrow stem cells. <i>Blood</i> , 2014 , 123, 310-1	2.2	2
57	A GMCSF and IL7 fusion cytokine leads to functional thymic-dependent T-cell regeneration in age-associated immune deficiency. <i>Clinical and Translational Immunology</i> , 2015 , 4, e37	6.8	2
56	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018 , 132, 1015-1015	2.2	2
55	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg \textregistered) for Advanced MDS and Secondary or Relapsed AML.. <i>Blood</i> , 2004 , 104, 1814-1814	2.2	2
54	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia 2020 , 8,		2
53	Circulating Progenitor Cells in Patients With Coronary Artery Disease and Renal Insufficiency. <i>JACC Basic To Translational Science</i> , 2020 , 5, 770-782	8.7	2
52	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 591-599		2

51	Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand) As a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S324-S325	4.7	2
50	Microfluidic Platform to Transduce Cell Viability to Distinct Flow Pathways for High-Accuracy Sensing. <i>ACS Sensors</i> , 2021 , 6, 3789-3799	9.2	2
49	Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3) study. <i>Contemporary Clinical Trials</i> , 2020 , 91, 105975	2.3	1
48	Association between recipient TNF rs361525 and acute GVHD: results from analysis of BMT CTN-0201 samples. <i>Bone Marrow Transplantation</i> , 2018 , 53, 1069-1071	4.4	1
47	A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Transfusion</i> , 2011 , 51, 1779-83	2.9	1
46	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 2157-2157	2.2	1
45	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. <i>Blood</i> , 2008 , 112, 3332-3332	2.2	1
44	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. <i>Blood</i> , 2010 , 116, 2305-2305	2.2	1
43	Incidence and geographic distribution of adult acute leukemia in the state of Georgia. <i>Southern Medical Journal</i> , 2014 , 107, 497-500	0.6	1
42	The Absence of Vasoactive Intestinal Peptide Augments Allo-Reactivity and the Anti-Viral Response in Bone Marrow Transplantation.. <i>Blood</i> , 2007 , 110, 3267-3267	2.2	1
41	A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD. <i>Blood</i> , 2012 , 120, 741-741	2.2	1
40	Allogeneic HSCT Patients Receiving More RBC Transfusions Are At Increased Risk For Development Of Grade 2-4 Acute Graft-Versus-Host Disease. <i>Blood</i> , 2013 , 122, 3298-3298	2.2	1
39	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020 , 123, 1228-1234	8.7	1
38	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research & Therapy</i> , 2016 , 6,	1	1
37	Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD. <i>Bone Marrow Transplantation</i> , 2019 , 54, 490-493	4.4	1
36	A new role for an old cytokine: GM-CSF amplifies GVHD. <i>Blood</i> , 2020 , 135, 520-521	2.2	1
35	Development of iron deficiency anemia in patients undergoing extracorporeal photopheresis: Comparison of the UVAR and CELLEX instruments. <i>Journal of Clinical Apheresis</i> , 2021 , 36, 34-40	3.2	1
34	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 4980-4991	7.8	1

33	Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. <i>Cytotherapy</i> , 2022 ,	4.8	1
32	Circulating progenitor cells are reduced in HIV-positive, anti-retroviral naïve patients. <i>International Journal of Cardiology</i> , 2014 , 176, 1150-2	3.2	0
31	Safety and Efficacy of Evomelañ Myeloma Autotransplants. <i>Blood</i> , 2018 , 132, 3446-3446	2.2	0
30	Associations Between Inflammation, Cardiovascular Regenerative Capacity, and Cardiovascular Events: A Cohort Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 2814-2822	9.4	0
29	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2020 , 136, 39-39	2.2	
28	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020 , 136, 20-21	2.2	
27	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020 , 136, 21-22	2.2	
26	MCMV Infection Lowers the Threshold for the Development of Clinical GvHD after Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2004 , 104, 2125-2125	2.2	
25	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. <i>Blood</i> , 2004 , 104, 3159-3159	2.2	
24	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. <i>Blood</i> , 2005 , 106, 4634-4634	2.2	
23	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. <i>Blood</i> , 2005 , 106, 2016-2016	2.2	
22	Prophylactic Amotosalen-Treated Donor T-Cells Prevent Late CMV Infection in Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2005 , 106, 3024-3024	2.2	
21	Allogeneic Transplantation for Multiple Myeloma 2008 , 125-142		
20	Vasoactive Intestinal Peptide Synthesis in Transplant Recipients Critically Regulate Donor T Cell Alloreactivity and Graft-Versus-Host Disease. <i>Blood</i> , 2018 , 132, 480-480	2.2	
19	Patulin Acts Synergistically with Doxorubicin and Bortezomib in Cytotoxicity against Hematological Malignancies. <i>Blood</i> , 2008 , 112, 2664-2664	2.2	
18	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. <i>Blood</i> , 2008 , 112, 3644-3644	2.2	
17	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2008 , 112, 1183-1183	2.2	
16	Flagellin, a TLR5 Agonist, Down-Regulate CD62L on Donor T Cells and Limit GvHD in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008 , 112, 3521-3521	2.2	

- 15 Donor Dendritic Cells Home to Lymphoid Organs in Allogeneic Transplant Recipients, Enhance Donor T-Cell Chimerism, and Polarize Donor T-Cell Activation.. *Blood*, **2009**, 114, 62-62 2.2
- 14 Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.. *Blood*, **2009**, 114, 1165-1165 2.2
- 13 A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.. *Blood*, **2009**, 114, 4230-4230 2.2
- 12 Prophylactic Use of Flagellin: A Novel Method to Boost Immune Reconstitution in Allogeneic HSCT Recipients with Limited GvHD.. *Blood*, **2009**, 114, 3561-3561 2.2
- 11 Targeting PKCtheta Inhibits Alloreactivity and Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia and Anti-Infection Activities.. *Blood*, **2009**, 114, 2458-2458 2.2
- 10 Thrombocytopenia Induced by Combination Administration of Romidepsin and Bortezomib In Mice Is Rapidly Reversible After Drug Treatment. *Blood*, **2010**, 116, 4909-4909 2.2
- 9 Flagellin, a TLR5 Agonist, Reduces GvHD in Allogeneic HSCT Recipients While Enhancing Anti-Viral Immunity: A Novel Therapeutic Approach. *Blood*, **2011**, 118, 144-144 2.2
- 8 Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. *Blood*, **2011**, 118, 1959-1959 2.2
- 7 Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. *Blood*, **2011**, 118, 2988-2988 2.2
- 6 Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients \geq 5 Years. *Blood*, **2011**, 118, 1015-1015^{2.2}
- 5 Advanced Non Small Cell Lung Cancer Patients with Fewer Numbers of Blood Myeloid Dendritic Cells and CD4 Cells Prior to Treatment Have Inferior Progression-Free Survival: Implications for Cancer Immunotherapy. *Blood*, **2012**, 120, 4837-4837 2.2
- 4 Incidence and Geographic Distribution of Adult Acute Lymphoblastic Leukemia in the State of Georgia. *Blood*, **2012**, 120, 4309-4309 2.2
- 3 Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America. *Blood*, **2013**, 122, 768-768 2.2
- 2 Expression Of PD-L1 Is Required To Control Acute GvHD In Allo-HSCT Recipients. *Blood*, **2013**, 122, 2008-2008 2.2
- 1 VIP-Receptor Antagonist Enhanced Antileukemic Activity In Mice. *Blood*, **2013**, 122, 1664-1664 2.2